\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
It adds to its broad-spectrum mechanism of action after other recent studies on BIT, ALS and tropical viruses.
VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ — TikoMed announced the inclusion in bioRxiv* of an in vitro study comparing the ability of the company’s leading ilb® drug candidate with:
inhibit the infection of human cells with the NL63 coronavirus evaluated by immunofluorescence of viral particles; and
directly block the interaction of the viral spike protein SARS-CoV-2 with the ACE2 receptor; and
modulate the subsequent consequences of viral infection by adding the reactive release of cytokines from induced human microglia through complex protein variants of SARS-CoV-2.
The study shows that ILB® blocked the interaction of the ACE2:spike protein and inhibited coronaviral infection. ILB® also attenuated the release of pro-inflammatory cytokines induced by omicrons, adding TNFa, from human microglia, indicating postviral neuroinflammation.
“These studies expand on our findings on the antiviral effect of ILB® on flavivirus infections that now come with the coronavirus. With ACE2, the key source site for SARS-CoV-2 to penetrate human cells,” said Professor Ann Logan PhD. (Professor of Regenerative Medicine and CSO, Axolotl Ltd).
Professor Nicholas Barnes PhD PBPhS (Professor of Pharmacology and Chief Executive Officer of Celentyx Ltd) also commented: “In pathological postviral fatigue syndromes such as prolonged COVID, a key mobile brain called microglia appears overactive and promotes related neuroinflammation. This knowledge has shown that microglia are calmed through ILB® in vitro and recommend that ILB® has the potential to inhibit neuroinflammation and therefore symptoms in patients with situations such as prolonged COVID.
TikoMed recently announced the publication of a peer-reviewed article on ILB’s® mode of action. In preclinical and clinical studies on a variety of neuroinflammation-induced diseases. , and restored cell function and homeostasis, https://doi. org/10. 3389/fphar. 2022. 983853.
In addition, TikoMed reported that ILB® inhibited human cells with dengue virus, Zika and yellow fever in vitro, https://www. biorxiv. org/content/10. 1101/2022. 08. 31. 503293v1. full.
Media:
International: Richard Hayhurst richard@rhapr. eu or 7711 821527
Nordic: Bjorkman Wave ola. bjorkman@letemknow. se or 70 245 7497
About Corona Viruses
Coronaviruses are a giant circle of relatives of pathogenic viruses wrapped in positive-stranded RNA that cause infectious diseases in animals and humans. For example, the highly transmissible virus SARS-CoV-2 causes coronavirus disease (COVID-19) that causes mild to moderate respiratory illness in most humans, but vulnerable Americans can become dangerously ill, spreading severe acute respiratory syndrome (SARS) and acute illness. Respiratory misery syndrome (ARDS) that can lead to organ damage [1]. The global pandemic of the COVID-19 disease that has spread since 2019 has had devastating health, social and economic consequences that remain severe[2]. As of August 2022, the World Health Organization reported 599,825,400 cases of COVID19 and 6,469,458 deaths (https://www. who. int/emergencies/diseases/novel-coronavirus-2019), accounting for just over 1% of those infected.
*bioRxiv is a flexible online archiving and distribution service for unpublished preprints in the life sciences. It is operated through Cold Spring Harbor Laboratory, a non-profit educational and study institution. By publishing preprints on bioRxiv, authors can make their findings without delay for the clinical network and get feedback on draft manuscripts before submitting them to journals.
For more important points about the “A clinical-stage LMW-DS drug inhibits cellular infection with coronavirus and modulates the reactive release of cytokines through microglia” examination, see publication: https://www. biorxiv. org/content/10. 1101/ 2022. 09. 07. 506919v1.
[1] Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS.
SARS-CoV-2 variants, vaccines and host immunity. Immunol before. 3 January 2022;12:809244. es what I:
10. 3389/fimmu. 2021. 809244. PMID: 35046961; PMCID: PMC8761766.
[2] Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The evolution of the epidemiology of SARS-CoV-2.
Science. 11 March 2022;375(6585):1116-1121. doi: 10. 1126/science. abm4915. Online of 10 March 2022.
PMID: 35271324; CDMP: PMC9009722
CONTACT:
Contact: info@tikomed. com or 46 42 23 40
These data were provided through Cision http://news. cision. com
https://news. cision. com/tikomed/r/tikomed-s-ilb–inhibits-cell-infection-by-coronaviruses-and-modulates-reactive-cytokine-release-from,c3629814
SOURCETikomed